We are live on ! Find out more
EPIX

ESSA Pharma
EPIX

Delisted

EPIX was delisted on the 8th of October, 2025.

Back to rankings

21 hedge funds and large institutions have $76.1M invested in ESSA Pharma in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

86% more capital invested

Capital invested by funds: $41M → $76.1M (+$35.1M)

31% more funds holding

Funds holding: 16 → 21 (+5)

16.38% less ownership

Funds ownership: 83.48% → 67.1% (-16%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
21
Holders Change
+5
Holders Change %
+31.25%
% of All Funds
0.41%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
6
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$59.6K
2
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$44.3K
3
AG
Advisor Group
Arizona
+$39.5K
4
Morgan Stanley
Morgan Stanley
New York
+$35.3K
5
Deutsche Bank
Deutsche Bank
Germany
+$7.29K

Top Sellers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$1.81K
2
TRCT
Tower Research Capital (TRC)
New York
-$516

EPIX Hedge Fund Activity: Q4 2019 in Review

21 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q4 2019, worth a combined $76.1M — up 86% from $41M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new EPIX positions and 1 closed out — a net gain of 5 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $59.6K. The largest seller was Royal Bank of Canada, cutting an estimated $1.81K.

  • 21 institutional investors held ESSA Pharma (EPIX) as of Q4 2019, up from 16 in Q3 2019.
  • Funds reported $76.1M of ESSA Pharma stock for Q4 2019, up 86% quarter-over-quarter.
  • 6 funds opened new ESSA Pharma positions in Q4 2019 and 1 closed out, a net change of +5 holders.
  • The largest ESSA Pharma buyer in Q4 2019 was Renaissance Technologies, an estimated $59.6K added.
  • The largest ESSA Pharma seller in Q4 2019 was Royal Bank of Canada, an estimated $1.81K sold.

Based on aggregated 13F filings for Q4 2019.